Guifeng Lin

机构：Sichuan University, Shijiazhuang Tiedao University · ORCID：0000-0002-2888-6099

发表论文 41 篇 · 总被引 1298 次 · h-index 16

代表论文

• An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron (2022 · Nature Microbiology · 被引 103)
• Molecular mechanism of allosteric modulation for the cannabinoid receptor CB1 (2022 · Nature Chemical Biology · 被引 102)
• Inhibition of METTL3 Alleviates NLRP3 Inflammasome Activation via Increasing Ubiquitination of NEK7 (2024 · Advanced Science · 被引 60)
• HDAC inhibitors improve CRISPR-Cas9 mediated prime editing and base editing (2022 · Molecular Therapy — Nucleic Acids · 被引 58)
• Discovery of a novel and potent inhibitor with differential species-specific effects against NLRP3 and AIM2 inflammasome-dependent pyroptosis (2022 · European Journal of Medicinal Chemistry · 被引 55)
• Structure-based identification of a G protein–biased allosteric modulator of cannabinoid receptor CB1 (2024 · Proceedings of the National Academy of Sciences · 被引 30)